Germany Lung Cancer Therapeutics Market: Segmented by Treatment Type, Cancer type, and Distribution channel - Growth, Trends, and Forecasts (2019 2028)
- Published Date: 2022-12-28
- Report ID: 139854
- Pages: 200
-
Format:
Report Overview
Germanys Lung Cancer Therapeutics market size stood at around USD 0.95 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of X.X% during the forecast period.
Germany faces the highest mortality rate (23.1 ASR per 100000) with respect to lung cancer and a greater number of cases are being registered year on year. Lung cancer cases are predominantly observed among the male population of Germany and as of 2020, almost 38436 new lung cancer cases have arisen among a total of 344451 cancer cases in Germany, attributing an astounding 11.2% of total cancer cases.
Smoking is thought of as the main cause of lung cancer, though lung cancer also follows in non-smokers.
Market Driving and Restraining Factors
Driving Factors
The driving factors for the growth of the Lung Cancer Therapeutics market in Germany include:
- Rising prevalence
- Increasing patient alertness
- Persistent investment in R&D
Growth in the lung cancer therapeutics market can also be attributed to patients constant contact with radiation and carcinogens. Furthermore, the late advent of disease symptoms leads to postponement in diagnosis and progression in the cancer stage, which results in the rising cost of the treatment, and thus makes higher revenues for the European treatment market.
Restraining Factors
- Adverse effects of therapeutics
1. Germany Lung Cancer Therapeutics Market Overview..................
A. Market Size
2. Market Driving and Restraining Factors.
A. Driving Factors
a. Rising prevalence
b. Increasing patient alertness
c. Persistent investment in R&D
B. Restraining Factors
a. Adverse effects of therapeutics
3. Lung Cancer Stages................................................................................
A. Stage I
B. Stage II
C. Stage III
D. Stage IV
4. Lung Cancer Therapeutics Market Segmentation........................
A. By Treatment Type
a. Chemotherapy
a. Cisplatin
b. Taxol
c. Navelbine
d. Camptosar
e. Alimta
b. Radiotherapy
a. External Beam
b. Internal Beam
c. Systemic
c. Other Drugs
a. Abraxane
b. Avastin
c. Crizotinib
d. Docetaxel
e. Gefitinib
B. By Cancer Type
a. Non-Small Cell Lung Cancer (NSCLC)
b. Small Cell Lung Cancer (SCLC)
C. By Distribution Channel
a. Hospital pharmacies
b. Ambulatory Surgical Centres
c. Retail and Online pharmacies
5. Lung Cancer Major Products Market Share
A. Market Analysis, Insights and Forecast By Revenue
6. Competitive Landscape
A. Major Players
B. Products in Pipeline
7. Key Company Profiles.
A. Boehringer Ingelheim GmbH Company overview, Product & Services, Strategies & Financials
B. Agennix AG Company overview, Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth
A. New Trends and Developments
B. Future Opportunities
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
